Kyrillus Shohdy, MD (@Kyrillus2) profile picture

Clinical Lecturer in Cancer Sciences @UoGlasgow, Honorary Medical Oncologist @NHSGGC, ex-Fellow @TheChristieNHS, @ASCO-LIFe Fellow @WeillCornell.

Glasgow
Joined July 2017
Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)Photo by Kyrillus Shohdy, MD (@Kyrillus2)
Kyrillus Shohdy, MD retweeted
🔥 CA209-8M4: nivolumab + TNT in locally advanced rectal cancer (ESMO Open, Phase II) 👥 29 pts, 96.6% MSS, chemoradiotherapy then mFOLFOX6 + nivolumab ✅ Composite mpCR 67.9%: 6/15 operated with pCR, 13 non-operative with cCR ≥12 mo ⏱️ 3-yr DFS 93%, 5-yr OS 97%, all assessable pts disease-free at 43.5 mo ⚠️ Grade ≥3 AEs 51.7%, one death; single-arm, self-defined endpoint Checkpoint inhibitors are not supposed to do much in MSS rectal cancer, and this trial is 96.6% MSS. A 67.9% composite complete-response rate, with nearly half the cohort avoiding surgery and nobody relapsing at 43.5 months, is a striking signal even after allowing for 29 patients and a self-defined endpoint. The 51.7% grade ≥3 toxicity rate and one death are the counterweight, and the randomised trial is what will tell us whether nivolumab is adding anything to a strong TNT backbone. Cross trial comparisons are very complicated here, not only to differences in the population but also **endpoint heterogeneity**: In PRODIGE 23, RAPIDO and UNION every patient went to surgery, so pCR is the only complete-response measure. CA209-8M4 and TORCH add cCR with W&W to the numerator, which inflates the composite relative to pCR-only trials. Another interesting is the timing of IO: NRG-GI002 gave pembrolizumab concurrently with long-course chemoRT, after induction FOLFOX. CA209-8M4 gave nivolumab after CRT, with consolidation mFOLFOX6. This may be better to boost response. #RectalCancer #Immunotherapy esmoopen.com/article/S2059-7…
🤖 Made with AI
2
19
1
50
3,605
Kyrillus Shohdy, MD retweeted
An RNA-editing enzyme restrains the excessive proliferation of intestinal stem cells—a major hallmark of #aging in humans and other organisms—according to new work involving fruit flies and data from mice and human samples. @IHuaXi scim.ag/4x2MTkw
4
11
1,064
Kyrillus Shohdy, MD retweeted
A previously unrecognized estrogen-dependent signaling pathway in the gut regulates visceral pain sensitivity in mice, according to a new Science study. The findings provide a pathway toward targeted therapeutic strategies. 📄: scim.ag/4rTYSz4 #SciencePerspective: scim.ag/4j8UAA6
4
89
7
336
31,832
Kyrillus Shohdy, MD retweeted
Cancer cell plasticity and resistance to KRAS inhibition Two recent preclinical examples in #ColorectalCancer @CD_AACR aacrjournals.org/cancerdisco… @Cancer_Cell cell.com/cancer-cell/fulltex…
2
29
1
120
9,471
Kyrillus Shohdy, MD retweeted
🔥off the press🔥 Cholangiocarcinoma 2026: status quo, unmet needs and priorities @NatRevGastroHep doi.org/10.1038/s41575-025-0… 👉get the lastest, most comprehensive summary on cholangiocarcinoma 👏fantastic team effort! @myESMO @EASLedu @ILCAnews
1
69
1
217
14,193
Kyrillus Shohdy, MD retweeted
How can a gene mutation be present throughout the body yet cause cancer only in certain tissues? This is exactly the challenge our SPECIFICANCER team took on 7 years ago. Read the newly published impact report from the team that reshaped our understanding of tissue specificity to pioneer potential new cancer treatments. Thank you to everyone involved for driving this ambitious science forward. Thanks also to our co-funders, @TheMarkFdn, for supporting the #CancerGrandChallenges SPECIFICANCER team and global science. Read the report: lnkd.in/eDrQ9guu
1
8
2
28
4,825
Kyrillus Shohdy, MD retweeted
Systemic review on neurocognitive outcomes in patients with🧠 metastases in @TheLancetOncol Urgent need for research assessing modality-specific neurocognitive tox and optimal sequencing of therapies! @OncoAlert #brainmets thelancet.com/journals/lanon…
2
9
23
3,830
Kyrillus Shohdy, MD retweeted
What’s true in #PancreaticCancer precursor lesions is also true in #ColorectalCancer precursor lesions. @cncurtis @SnyderShot @StanfordMed demonstrate polyclonal origin of adenomas in patients with FAP. Cancer as a manifestation of convergent evolution! nature.com/articles/s41586-0…
2
60
8
207
61,306
Groundbreaking work just came today from  @owen_sansom Lab, spearheaded by Mark White and exceptionally talented team @CRUKScotland & @UoFGlasgow The work unmasked MAPK-driven Colorectal Cancer's clever escape from therapy. Yes Always search for the WNT.  nature.com/articles/s41586-0…
3
5
1,147
Paneth-like transition drives resistance to dual targeting of KRAS & EGFR in CRC ✅CRC cells surviving combined KRAS & EGFR inhibition acquire Paneth-like state ✅SMAD1-FGFR3 axis triggers Paneth-like plasticity ✅FGFR3 blockade could overcome plasticity-driven drug tolerance @OncoAlert @Cancer_Cell cell.com/cancer-cell/fulltex…
12
47
6,756
Kyrillus Shohdy, MD retweeted
Provocative new data in @NatureMedicine from @JenWargoMD @nadim_ajami & colleagues @MDAndersonNews Microbial signals in primary and metastatic brain tumors nature.com/articles/s41591-0… Orthogonal validation using multiple platforms provides support for this observation
15
2
62
21,608
Kyrillus Shohdy, MD retweeted
📌Inaccurate lymph node clinical staging in early and intermediate-risk rectal cancer @EORTC 🚨19.5% understaged and 62.4% overstaged ✅Seems no survival effect ➡️At least a destressing data when MRI shows 1-3 small lymph nodes that we can not decide whether pathologic or not 👉ejcancer.com/article/S0959-8… #cancer #oncology #MedX #rectal @OncoAlert @realbowtiedoc @GIMedOnc
4
17
40
5,257
Kyrillus Shohdy, MD retweeted
ANOVA in R! 💪 in ONE LINE OF CODE! ggstatsplot::ggbetweenstats(ISLR::Wage, race, wage) Watch the video for more details: youtu.be/JDGtLG0Tceo #rstats #statistics #dataanalysis #stats #datascience #r4ds
4
84
4
499
41,170
Kyrillus Shohdy, MD retweeted
🍽️ Turning “no appetite” into “pass the plate” with olanzapine 📝 JNCCN 2025 | OlAnCa trial | DB RCT | n=164 | Cairo Univ 🔑 Trial essentials • 🌐 Incurable solid tumors + cachexia • 🎲 Randomized: Olanzapine 5 mg QHS vs placebo • 🎯 Primary: Appetite (ESAS-Anorexia) @ 1 wk 📊 Results 🍴 Appetite ↑ more with olanzapine (–2 vs –1; p=0.003) ⚖️ ≥5% weight gain: 14% vs 0% (p=0.008) 😀 QoL (FAACT-ACS) improved 💪 BUT ↓ handgrip strength (–2.8 kg) & ↑ grade ≥3 anemia/leukopenia 💡 Takeaway Olanzapine 5 mg = rapid appetite & weight gains in cachexia — but ⚠️ safety & durability remain open questions. 📓Othman NO, et al. JNCCN. 2025;23(9):385–392. 🔗DOI: jnccn.org/abstract/journals/… #OncoTwitter #MedTwitter #PalliativeCare #Cachexia @OncoAlert @myesmo @asco @JNCCN
4
31
2
115
11,055
Kyrillus Shohdy, MD retweeted
#USCAP2025 w/ Dr Voltaggio Esophageal ⬆️ grade dysplasia/intramucosal adeno → treated with EMR. Presence of muscularis mucosa = lateral margin; large vessels + loose CT = deep margin. Recommendation to pin specimen before fixing for easier margin assessment. #PathWebinarPearls
2
38
90
4,729
Kyrillus Shohdy, MD retweeted
New review: Mellor, Larson, and @DrMengWang discuss the molecular mechanisms of mammalian genomic instability arising from folate deficiency and how this impacts genome biology in health and disease. hubs.la/Q03D97r20 #CellMetabolism
4
7
1,300
Kyrillus Shohdy, MD retweeted
New Paper Alert: BRCA1/2 Mutations and RB1 Alterations Predict Poorer Outcomes With Endocrine Therapy ± CDK4/6 Inhibitors in HR+/HER2– Breast Cancer Authors: Hamdy A. Azim, Hagar Elghazawy (@HagarElghazawy1), Kyrillus S. Shohdy (@Kyrillus2 ) Shaimaa Lasheen, Mahmoud Elghazawy, Ramy Ghazy, Dalia Abdelnasser, Loay Kassem (@L0AY_Kassem) oncodaily.com/new-paper-aler… #Cancer #Oncology #OncoDaily #Health #Medicine @CancerWorldmag
1
1
5
270